What is the recommended dose of Amphotericin B (antifungal medication) for neonates?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosing of Amphotericin B in Neonates

For neonates with invasive candidiasis, amphotericin B deoxycholate should be administered at a dose of 1 mg/kg/day intravenously as a single daily dose. 1

Amphotericin B Formulations for Neonates

Conventional Amphotericin B (Deoxycholate)

  • First-line therapy for invasive candidiasis in neonates at 1-1.5 mg/kg/day intravenously as a single daily dose 1
  • Pharmacokinetics in neonates are relatively poorly defined, leading to some uncertainty regarding optimal dosage for hematogenous Candida meningoencephalitis (HCME) 1
  • Nephrotoxicity appears less pronounced in neonates compared to older children and adults 2
  • Monitoring of renal function and potassium levels is essential during treatment 2
  • Sodium supplementation (4 mEq/kg/day) may significantly reduce nephrotoxicity 3

Liposomal Amphotericin B

  • Recommended at 2.5-7 mg/kg/day intravenously as a single daily dose 1
  • Not approved for use in infants <1 month of age 1
  • Higher doses (5-7 mg/kg/day) have shown effectiveness with fungal eradication achieved in 95% of cases 4
  • Better safety profile than conventional amphotericin B, particularly regarding nephrotoxicity 5, 6
  • Consider for neonates with renal impairment or those at high risk for nephrotoxicity 3

Amphotericin B Lipid Complex (ABLC)

  • Alternative option at 2.5-5 mg/kg/day intravenously as a single daily dose 1
  • Graded as C-II (lower evidence) due to relative paucity of clinical data 1
  • Preclinical data suggests effectiveness for HCME 1

Clinical Considerations

Monitoring During Treatment

  • Monitor renal function with serum creatinine at baseline and regularly during treatment 2
  • Monitor serum potassium levels due to risk of hypokalemia (<3.0 mmol/L) which occurs in approximately 17% of treated neonates 2
  • Follow blood cultures to document clearance of infection 4

Duration of Therapy

  • Median duration of therapy is approximately 18 days 4
  • Continue treatment until fungal eradication is achieved (median time to eradication: 8-11 days) 4
  • For HCME, longer treatment courses may be necessary 1

Special Considerations

  • Elevated serum creatinine typically resolves by the end of amphotericin B therapy in most neonates 2
  • Consider higher doses of liposomal amphotericin B (up to 7 mg/kg/day) for difficult-to-treat infections 4
  • First-line therapy with high-dose liposomal amphotericin B may achieve more rapid fungal eradication than when used as second-line therapy 4

Alternative Antifungal Options for Neonates

  • Fluconazole: 12 mg/kg/day with consideration of a 25 mg/kg loading dose 1
  • Micafungin: 4-10 mg/kg/day IV (higher doses for suspected HCME) 1
  • Caspofungin: 25 mg/m²/day 1

Common Pitfalls and Caveats

  • Underestimating the importance of monitoring renal function and electrolytes during treatment 2
  • Premature discontinuation of therapy before achieving fungal eradication 4
  • Failure to consider CNS involvement (HCME) when treating neonatal candidiasis 1
  • Not adjusting dosing based on the specific amphotericin B formulation being used 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Nephrotoxicity associated with amphotericin B deoxycholate in neonates.

The Pediatric infectious disease journal, 2009

Research

High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2003

Research

Liposomal amphotericin B treatment for neonatal fungal infections.

The Pediatric infectious disease journal, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.